• Publications
  • Influence
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
Modulating protein ubiquitination via proteasome inhibition represents a promising target for cancer therapy, because of the higher sensitivity of cancer cells to the cytotoxic effects of proteasomeExpand
  • 224
  • 12
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
The ubiquitin-proteasome pathway plays a central role in regulation of the production and destruction of cellular proteins. These pathways mediate proliferation and cell survival, particularly inExpand
  • 127
  • 5
High-performance liquid chromatography-electrospray ionization mass spectrometry and multiple mass spectrometry studies of hyperforin degradation products.
The alcoholic extract of the aerial parts of Hypericum perforatum L. finds wide application because of its antidepressant activity. The extract contains a number of constituents with documentedExpand
  • 40
  • 1
Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer
Background Preclinical models have reported a synergistic interaction between sorafenib and vinorelbine. We investigated the toxicity, efficacy, and pharmacokinetics interaction of this combinationExpand
  • 8
  • 1
  • PDF
Biodistribution of paclitaxel poliglumex (PPX) in lung: Analysis of gender-related alterations in a preclinical model.
17003 Background: PPX is a macromolecular drug conjugate that links paclitaxel with poly-L-glutamic acid; the release of paclitaxel is dependent on metabolism by lysosomal proteases, particularlyExpand
  • 3
  • 1